No translate

Trần Đình Bình; Trần Thanh Loan

doi:10.58354/jvc.93.2021.1254

BÀI TỔNG QUAN Issue: Số 93, 2021 TĂNG HUYẾT ÁP

No translate

Trần Đình Bình: Trường Đại học Y Dược, Đại học Huế; Trần Thanh Loan: Bộ môn Miễn dịch-Sinh lý bệnh, Trường Đại học Y Dược, Đại học Huế;

Published: August 21, 2026

10.58354/jvc.93.2021.1254

Abstract

No translate

Keywords

No translate

References

Wu C, Chen X, Cai Y, et al. (2020). Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med, published online 13 March (doi:10.1001/jamainternmed.2020.0994).

DOI: doi.org/10.1001/jamainternmed.2020.0994

Fox, Dan (2020). “What you need to know about the Wuhan coronavirus”. Nature. ISSN 0028-0836.

DOI: doi.org/10.1038/d41586-020-00209-y

Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 2020 May.

DOI: doi.org/10.1001/jama.2020.8707

Vaduganathan M, Vardeny O, Michel T, et al. (2020). Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med;382:1653–1659.

DOI: doi.org/10.1056/nejmsr2005760

Wang Z, Chen Z, Zhang L, et al. (2018). Status of hypertension in China: results from the China Hypertension Survey, 2012-2015. Circulation;137:2344–2356.

Zhou F, Yu T, Du R, et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet; 395:497–506.

DOI: doi.org/10.1001/jamainternmed.2020.0994

Gaetano Ruocco et al. Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. International Journal of Infectious Diseases 95 (2020) 373–375.

DOI: doi.org/10.1016/j.ijid.2020.04.058

Arnett DK, Blumenthal RS, Albert MA, et al. (2019). ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol;74:e177–232.

10.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell; 181:1–10.

11.

Furuhashi M, Moniwa N, Mita T, et al (2020). Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens 2015; 28:15–21.

12.

Imai Y, Kuba K, Rao S, et al. (2020). Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature; 436:112–116.

DOI: doi.org/10.1001/jamacardio.2019.2604

13.

Phadke M, Saunik S. (2020). Rapid response: use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections—novel mode of treatment. Response to the emerging novel coronavirus outbreak. Br Med J; 368:m406.

14.

Zheng YY, Ma YT, Zhang JY, Xie X. (2020). COVID-19 and the cardiovascular system. Nat Rev Cardiol, published online 5 March. (doi:10.1038/s41569-020-0360-5).

DOI: doi.org/10.1038/s41569-020-0360-5

15.

Gurwitz D. (2020). Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020, published online 4 March; doi: 10.1002/ddr.21656.

DOI: doi.org/10.1002/ddr.21656

16.

Batlle D, Wysocki J, Satchell K. (2020). Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond); 134:543–545.

DOI: doi.org/10.1093/ajh/hpu086

17.

Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of covid-19. N Engl J Med. 2020;382:2431–2440.

18.

Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of covid-19. N Engl J Med. 2020;382:2441–2448.

19.

Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P. Association of use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1020–1026.